Stereotactic Body Radiotherapy for Central and Ultracentral Lung Tumors: A Multicenter Real-world Outcomes Analysis


Akgün Z., Ahmadova A., Atalar B., Demircan V., DEMİR S., Güney Y., ...Daha Fazla

Clinical Oncology, cilt.60, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 60
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1016/j.clon.2026.104341
  • Dergi Adı: Clinical Oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE, Academic Search Ultimate (EBSCO)
  • Anahtar Kelimeler: Central, lung tumors, stereotactic body radiotherapy, toxicity, tumor control, ultracentral
  • Ankara Üniversitesi Adresli: Evet

Özet

Aims: The aim of the study is to evaluate real-world clinical outcomes of stereotactic body radiotherapy (SBRT) for central (C) and ultracentral (UC) lung tumors, with a focus on toxicity, tumor control, and overall survival (OS). Materials and Methods: This multicenter retrospective analysis included 133 patients with C or UC lung tumors treated with SBRT across multiple participating centers. Patient characteristics, treatment parameters, toxicity outcomes, tumor control, and OS were analyzed retrospectively. Results: Grade 2 toxicity occurred in 30.1% (n = 31/103) of patients with C tumors and 26.7% (n = 8/30) with UC tumors, while grade 3 toxicity was observed in 8.7% and 16.7% of patients, respectively. Median OS was 24 months. Favorable outcomes were observed in patients with epidermal growth factor receptor (EGFR)-mutant disease and smaller planning target volumes (PTVs). Delivery of SBRT in conjunction with systemic therapies was feasible and associated with manageable toxicity profiles. Conclusion: In this multicenter real-world cohort, SBRT for C and UC lung tumors was associated with acceptable toxicity and clinically meaningful outcomes when delivered using contemporary techniques and cautious fractionation. Observations in selected subgroups, including patients with EGFR-mutant disease and smaller PTVs, should be interpreted as hypothesis-generating and support individualized clinical decision-making in anatomically high-risk settings.